Daniël P. van Kammen

10.0k total citations
218 papers, 7.6k citations indexed

About

Daniël P. van Kammen is a scholar working on Psychiatry and Mental health, Cellular and Molecular Neuroscience and Cognitive Neuroscience. According to data from OpenAlex, Daniël P. van Kammen has authored 218 papers receiving a total of 7.6k indexed citations (citations by other indexed papers that have themselves been cited), including 110 papers in Psychiatry and Mental health, 67 papers in Cellular and Molecular Neuroscience and 42 papers in Cognitive Neuroscience. Recurrent topics in Daniël P. van Kammen's work include Schizophrenia research and treatment (89 papers), Tryptophan and brain disorders (37 papers) and Neurotransmitter Receptor Influence on Behavior (29 papers). Daniël P. van Kammen is often cited by papers focused on Schizophrenia research and treatment (89 papers), Tryptophan and brain disorders (37 papers) and Neurotransmitter Receptor Influence on Behavior (29 papers). Daniël P. van Kammen collaborates with scholars based in United States, United Kingdom and Canada. Daniël P. van Kammen's co-authors include Jeffrey Yao, Ravinder Reddy, Mary E. Kelley, Steven D. Forman, John A. Gurklis, Dennis L. Murphy, Stuart R. Steinhauer, William E. Bunney, Daniel N. Allen and John P. Docherty and has published in prestigious journals such as Science, New England Journal of Medicine and JAMA.

In The Last Decade

Daniël P. van Kammen

216 papers receiving 7.1k citations

Peers

Countries citing papers authored by Daniël P. van Kammen

Since Specialization

Citations

This map shows the geographic impact of Daniël P. van Kammen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniël P. van Kammen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniël P. van Kammen more than expected).

Fields of papers citing papers by Daniël P. van Kammen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniël P. van Kammen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniël P. van Kammen. The network helps show where Daniël P. van Kammen may publish in the future.

Co-authorship network of co-authors of Daniël P. van Kammen

This figure shows the co-authorship network connecting the top 25 collaborators of Daniël P. van Kammen. A scholar is included among the top collaborators of Daniël P. van Kammen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniël P. van Kammen. Daniël P. van Kammen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pharmacokinetics, Tolerability, and Safety of ACP‐103 Following Single or Multiple Oral Dose Administration in Healthy Volunteers 2007 ·The Journal of Clinical Pharmacology ·Kimberly E. Vanover, (unknown), (unknown), Timothy Mant, Daniël P. van Kammen, Robert E. Davis, David M. Weiner	30
2	NOTCH4 gene haplotype is associated with schizophrenia in African Americans 2003 ·Biological Psychiatry ·Xingguang Luο, Tim Klempan, Jaakko Lappalainen, Robert A. Rosenheck, Dennis S. Charney, Joseph Erdos, Daniël P. van Kammen, Henry R. Kranzler, James L. Kennedy, Joel Gelernter	25
3	Factor structure of neurologic examination abnormalities in unmedicated schizophrenia 2000 ·Psychiatry Research ·Richard D. Sanders, Matcheri S. Keshavan, Steven D. Forman, (unknown), Nancy McLaughlin, Daniel N. Allen, Daniël P. van Kammen, Gérald Goldstein	50
4	Modulation of language processing in schizophrenia: effects of context and haloperidol on the event-related potential 1999 ·Biological Psychiatry ·Ruth Condray, Stuart R. Steinhauer, Jonathan D. Cohen, Daniël P. van Kammen, Annette Kasparek	67
5	Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia 1998 ·Biological Psychiatry ·Guochuan Tsai, Daniël P. van Kammen, Chen Shao, Mary E. Kelley, (unknown), Joseph T. Coyle	61
6	Utility of WAIS-R short forms in schizophrenia 1997 ·Schizophrenia Research ·Daniel N. Allen, (unknown), John A. Gurklis, Mary E. Kelley, (unknown), Daniël P. van Kammen	23
7	Decreased serotonergic responsivity in platelets of drug-free patients with schizophrenia 1996 ·Psychiatry Research ·Jeffrey Yao, Daniël P. van Kammen, Howard B. Moss, (unknown)	27
8	Working memory capacity predicts language comprehension in schizophrenic patients 1996 ·Schizophrenia Research ·Ruth Condray, Stuart R. Steinhauer, Daniël P. van Kammen, Annette Kasparek	63
9	Language comprehension in schizophrenia: Trait or state indicator? 1995 ·Biological Psychiatry ·Ruth Condray, Daniël P. van Kammen, Stuart R. Steinhauer, Annette Kasparek, Jeffrey Yao	33
10	Cerebrospinal fluid corticotropin-releasing factor increases following haloperidol withdrawal in chronic schizophrenia 1994 ·Schizophrenia Research ·Steven D. Forman, Garth Bissette, Jeffrey Yao, Charles B. Nemeroff, Daniël P. van Kammen	18
11	Memory and plasma HVA changes in schizophrenia: Are they episode markers? 1994 ·Biological Psychiatry ·Mark W. Gilbertson, Jeffrey K Yao, Daniël P. van Kammen	6
12	Electroencephalographic sleep in clinically stable Schizophrenic Patients: Two-weeks versus six-weeks neuroleptic-free 1993 ·Biological Psychiatry ·Eric A. Nofzinger, Daniël P. van Kammen, Mark W. Gilbertson, John A. Gurklis, (unknown)	36
13	CSF NORADRENERGIC ACTIVITY AND SLEEP EEG IN CLINICALLY STABLE SCHIZOPHRENIC PATIENTS AFTER HALOPERIDOL WITHDRAWAL. 1992 ·Clinical Neuropharmacology ·Daniël P. van Kammen, Jianing Yao, John A. Gurklis, Dennis O’Connor, Eric A. Nofzinger, Jeffrey L. Peters	1
14	Dopamine and norepinephrine activity in schizophrenia 1991 ·Schizophrenia Research ·Daniël P. van Kammen, Mary E. Kelley	79
15	CSF chromogranin A-like immunoreactivity in schizophrenia 1991 ·Schizophrenia Research ·Daniël P. van Kammen, (unknown), Jeffrey Yao, Thomas C. Neylan, (unknown), (unknown), Daniel T. O’Connor	15
16	Neuropeptide Y-like immunoreactivity in schizophrenia 1990 ·Schizophrenia Research ·(unknown), Daniël P. van Kammen, Joel Gelernter, Jeffrey Yao, David Shaw	33
17	Models for the development of the visual cortex 1989 ·Addison-Wesley Longman Publishing Co., Inc. eBooks ·Alan Yuille, Daniël P. van Kammen	2
18	No effect of haloperidol on cerebrospinal fluid acetylcholinesterase in patients with schizophrenia 1988 ·Biological Psychiatry ·F. Jacob Huff, (unknown), Jules Rosen, Jeffrey L. Peters, Daniël P. van Kammen	7
19	Schizophrenia: Instability in Norepinephrine, Serotonin, and γ-Aminobutyric Acid Systems 1988 ·International review of neurobiology ·Joel Gelernter, Daniël P. van Kammen	18
20	Amphetamine increases prolactin but neither growth hormone nor β-endorphin immunoreactivity in schizophrenic patients 1981 ·S. Charles Schulz, Daniël P. van Kammen, Alan D. Rogol	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact